2/14/2011
CEO'S COMMENTS
As I predicted and communicated last year, fiscal 2010 was somewhat of an off-year for company growth. I would rather characterize the year past as a very eventful year.
Meda's pipeline has been further strengthened, and several products have made great headway during the year such as flupirtine (treatment of fibromyalgia).
Meda's focus on growth markets, such as Russia, Turkey, Poland, and Mexico, has also shown excellent results in 2010 with an average increase in sales of more than 20 percent
http://www.cisionwire.com/meda/meda-ab--publ----2010-year-end-report85727
Meda's pipeline has been further strengthened, and several products have made great headway during the year such as flupirtine (treatment of fibromyalgia).
Meda's focus on growth markets, such as Russia, Turkey, Poland, and Mexico, has also shown excellent results in 2010 with an average increase in sales of more than 20 percent
http://www.cisionwire.com/meda/meda-ab--publ----2010-year-end-report85727
No comments:
Post a Comment